News

tranScrip (www.transcrip-partners.com) is delighted to be supporting Synairgen with their first patient dosing in a trial of SNG001 in COVID-19.


tranScrip's support in this important endeavour is a continuation of being at the heart of the development of SNG001 (inhaled formulation of interferon-beta-1a) for the last 12 years.

Cambridge, UK - 6 April 2020 - Healx, the AI-powered, patient-inspired biotech specialising in rare diseases, today announces it is using its AI platform to develop drug combinations from approved drugs to contribute towards global efforts to find treatments for COVID-19. This focus on combination therapies, where two or more drugs simultaneously target different aspects of the disease pathology, has the potential to ensure a more effective treatment.

Cambridge, UK, 03 April 2020: Horizon Discovery Group plc (LSE: HZD) (“Horizon”, “the Company” or “the Group”), a global leader in the application of gene editing and gene modulation for cell line engineering, today announced the addition of an arrayed CRISPR knockout screening service for primary human B cells to its cell-based screening services.

I’ve worked from home for 9 years, starting off as Head of R&D for a virtual biotech, then as CEO of Agility Health Tech. For the last few years, I’ve hardly been at home, I was mostly on site with clients, talking at events or meeting with potential new clients. Until two weeks ago…

Following on from the success of our first webinar on EU GMP Annex 1 - Implications for Sterile Products Manufacture, RSSL are gearing up for the second installment of their three-part webinar series on manufacturing sterile pharmaceuticals.


The second webinar, to be held 6 May, will be on the topic of Reviewing Sterile Products - Examining the Factors Required for Release and will again be hosted by Dr Tim Sandle.

Join a COVID-19 marketing mastermind group to get a fresh perspective and new ideas during these challenging times.

AMSBIO report on a world first clinical study of iPSC-derived corneal epithelial cells by Professor Ryuhei Hayashi and co-workers from the Graduate School of Medicine, Osaka University, Japan using StemFit Basic03 clinical grade stem cell culture medium and iMatrix-511 recombinant laminin E8 fragments.

Cambridge, UK, and Budapest, Hungary, 31 March 2020: Horizon Discovery Group plc (LSE: HZD) (“Horizon”, “the Company” or “the Group”), a global leader in the application of gene editing and gene modulation for cell line engineering, and Pharmahungary Group, a preclinical and clinical R&D company, today announced positive early-stage results for a novel micro-RNA therapeutic for ischemic heart diseases.

With the uncertainties around how the COVID-19 situation will develop all businesses, of course, are considering what they feel to be responsible and proportionate courses of action to take to protect themselves and others. One Nucleus is doing likewise, making these judgments in light of UK Government advice in the interests of staff, members and our wider network. To keep our contacts informed, our current view is as follows:

Pages